Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free TPST Stock Alerts

Tempest Therapeutics (TPST) Financials

Tempest Therapeutics logo
$0.97 -0.01 (-1.04%)
Closing price 04:00 PM Eastern
Extended Trading
$1.00 +0.03 (+3.00%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Tempest Therapeutics

Annual Income Statements for Tempest Therapeutics

This table shows Tempest Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -73 -82 -85 -27 -45 -19 -28 -36 -29 -42 -26
Consolidated Net Income / (Loss)		 -73 -82 -85 -27 -45 -19 -28 -36 -29 -42 -26
Net Income / (Loss) Continuing Operations		 -73 -82 -85 -27 -45 -19 -28 -36 -29 -42 -26
Total Pre-Tax Income 		-73 -82 -85 -27 -45 -19 -28 -36 -29 -42 -26
Total Operating Income		 -72 -81 -84 -27 -45 -19 -27 -35 -29 -42 -27
Total Gross Profit		 -1.97 -4.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.28 0.65 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 2.25 5.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 70 76 84 27 45 19 27 35 29 42 27
Selling, General & Admin Expense		 52 49 5.96 12 18 4.91 9.82 12 12 14 14
Research & Development Expense		 18 22 78 14 28 14 17 23 17 28 13
Total Other Income / (Expense), net		 -1.15 -1.05 -0.26 -0.30 0.83 0.18 -1.32 -1.07 -0.33 0.18 0.31
Interest Expense		 - - 0.29 - - 0.00 1.28 1.62 1.45 1.32 0.21
Other Income / (Expense), net		 -0.02 -0.16 0.03 -0.17 -0.21 0.18 -0.03 0.55 1.12 1.50 0.52
Income Tax Expense		 0.08 0.20 - - - 0.00 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($2.70) ($2.56) ($321.81) ($17.58) ($3.25) ($41.03) ($7.47) ($3.09) ($1.91) ($19.50) ($6.33)
Weighted Average Basic Shares Outstanding		 27.09M 32.15M 262.82K 1.55M 13.71M 468.16K 3.79M 11.55M 15.42M 2.15M 4.15M
Diluted Earnings per Share		 ($2.70) ($2.56) ($321.81) ($17.58) ($3.25) ($41.03) ($7.47) ($3.09) ($1.91) ($19.50) ($6.33)
Weighted Average Diluted Shares Outstanding		 27.09M 32.15M 262.82K 1.55M 13.71M 468.16K 3.79M 11.55M 15.42M 2.15M 4.15M
Weighted Average Basic & Diluted Shares Outstanding		 27.09M 32.15M 262.82K 1.55M 13.71M 18.86M 7.17M 10.56M 22.19M 45.48M 14.34M

Quarterly Income Statements for Tempest Therapeutics

This table shows Tempest Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -6.79 -7.49 -7.90 -9.57 -11 -14 -11 -7.87 -3.51 -4.02 -28
Consolidated Net Income / (Loss)		 -6.79 -7.49 -7.90 -9.57 -11 -14 -11 -7.87 -3.51 -4.02 -28
Net Income / (Loss) Continuing Operations		 -6.79 -7.49 -7.90 -9.57 -11 -14 -11 -7.87 -3.51 -4.02 -28
Total Pre-Tax Income 		-6.79 -7.49 -7.90 -9.57 -11 -14 -11 -7.87 -3.51 -4.02 -28
Total Operating Income		 -6.59 -7.51 -7.97 -9.58 -11 -14 -11 -7.97 -3.60 -4.08 -28
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 6.59 7.51 7.97 9.58 11 14 11 7.97 3.60 4.08 28
Selling, General & Admin Expense		 2.37 3.33 3.63 3.75 2.99 3.18 3.31 4.10 3.03 3.54 5.43
Research & Development Expense		 4.22 4.18 4.34 5.84 7.56 11 7.63 3.87 0.57 0.54 22
Total Other Income / (Expense), net		 -0.19 0.03 0.07 0.01 -0.01 0.11 0.08 0.10 0.09 0.06 0.02
Interest Expense		 0.37 0.38 0.37 0.37 0.33 0.25 0.16 0.05 0.00 - 0.00
Other Income / (Expense), net		 0.18 0.40 0.44 0.38 0.32 0.35 0.24 0.14 0.09 0.06 0.02
Income Tax Expense		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.48) ($0.34) ($4.62) ($5.52) ($5.32) ($6.44) ($3.16) ($2.07) ($0.79) ($0.97) ($2.53)
Weighted Average Basic Shares Outstanding		 14.12M 15.42M 1.71M 1.73M 1.99M 2.15M 3.44M 3.80M 4.44M 4.15M 10.93M
Diluted Earnings per Share		 ($0.48) ($0.34) ($4.62) ($5.52) ($5.32) ($6.44) ($3.16) ($2.07) ($0.79) ($0.97) ($2.53)
Weighted Average Diluted Shares Outstanding		 14.12M 15.42M 1.71M 1.73M 1.99M 2.15M 3.44M 3.80M 4.44M 4.15M 10.93M
Weighted Average Basic & Diluted Shares Outstanding		 19.25M 22.19M 22.22M 25.21M 43.64M 45.48M 3.68M 4.44M 4.44M 14.34M 14.81M

Annual Cash Flow Statements for Tempest Therapeutics

This table details how cash moves in and out of Tempest Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 37 0.71 -24 56 -10 16 33 -20 8.08 -8.96 -23
Net Cash From Operating Activities		 -50 -62 -20 -24 -41 -19 -26 -31 -27 -33 -27
Net Cash From Continuing Operating Activities		 -50 -62 -20 -24 -41 -19 -26 -31 -28 -33 -27
Net Income / (Loss) Continuing Operations		 -73 -82 -85 -27 -45 -19 -28 -36 -29 -42 -26
Consolidated Net Income / (Loss)		 -73 -82 -85 -27 -45 -19 -28 -36 -29 -42 -26
Depreciation Expense		 1.30 2.20 0.03 0.03 0.10 0.34 0.37 0.64 0.38 0.39 0.27
Non-Cash Adjustments To Reconcile Net Income		 21 13 66 2.46 4.35 0.92 2.58 3.13 2.61 6.81 4.31
Changes in Operating Assets and Liabilities, net		 -0.53 4.58 -1.84 1.04 -2.05 -1.07 -0.61 0.87 -1.05 1.61 -5.13
Net Cash From Investing Activities		 -38 8.29 0.46 1.93 3.99 -0.01 -0.10 -0.56 -0.17 -0.44 0.00
Net Cash From Continuing Investing Activities		 -38 8.29 0.46 1.93 3.99 -0.01 -0.10 -0.56 -0.17 -0.44 0.00
Purchase of Property, Plant & Equipment		 -5.23 -2.59 -0.00 -0.04 -0.40 -0.05 -0.14 -0.56 -0.17 -0.44 0.00
Net Cash From Financing Activities		 125 54 -4.46 78 27 35 59 11 36 25 4.26
Net Cash From Continuing Financing Activities		 125 54 -4.46 78 27 35 59 11 36 25 4.26
Repayment of Debt		 - - -10 -1.52 -0.20 0.00 -0.10 -4.74 0.00 -4.40 -6.43
Issuance of Common Equity		 125 54 - 39 27 0.00 33 16 36 29 11
Cash Interest Paid		 - - 0.21 - - 0.00 0.95 1.54 1.25 1.18 0.19

Quarterly Cash Flow Statements for Tempest Therapeutics

This table details how cash moves in and out of Tempest Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -6.47 28 -6.90 -1.20 -8.66 7.80 -8.76 -7.23 -6.77 0.19 -5.90
Net Cash From Operating Activities		 -6.49 -6.18 -7.19 -5.51 -10 -10 -8.04 -8.43 -6.78 -3.57 -7.60
Net Cash From Continuing Operating Activities		 -6.39 -6.36 -7.19 -5.51 -10 -10 -8.04 -8.43 -6.78 -3.57 -7.60
Net Income / (Loss) Continuing Operations		 -6.79 -7.49 -7.90 -9.57 -11 -14 -11 -7.87 -3.51 -4.02 -28
Consolidated Net Income / (Loss)		 -6.79 -7.49 -7.90 -9.57 -11 -14 -11 -7.87 -3.51 -4.02 -28
Depreciation Expense		 0.09 0.09 0.09 0.16 0.10 0.05 0.07 0.07 0.07 0.07 0.06
Non-Cash Adjustments To Reconcile Net Income		 1.13 -0.25 1.81 1.73 1.64 1.64 1.69 1.40 0.34 0.87 20
Changes in Operating Assets and Liabilities, net		 -0.82 1.29 -1.18 2.18 -1.36 1.98 1.06 -2.03 -3.68 -0.49 -0.41
Net Cash From Investing Activities		 - -0.01 -0.17 -0.25 -0.02 -0.00 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - -0.01 -0.17 -0.25 -0.02 -0.00 0.00 - - - 0.00
Purchase of Property, Plant & Equipment		 - -0.01 -0.17 -0.25 -0.02 -0.00 0.00 - - - 0.00
Net Cash From Financing Activities		 0.02 34 0.45 4.56 1.54 18 -0.72 1.20 0.01 3.77 1.70
Net Cash From Continuing Financing Activities		 0.02 34 0.45 4.56 1.54 18 -0.72 1.20 0.01 3.77 1.70
Repayment of Debt		 - - 0.00 - -2.20 -2.20 -2.20 -4.23 - - 0.00
Issuance of Common Equity		 0.02 34 0.45 4.56 3.74 20 1.48 5.43 0.01 3.77 1.70
Cash Interest Paid		 0.32 0.32 0.33 0.33 0.30 0.22 0.15 0.04 - - 0.00
Cash Income Taxes Paid		 - - 0.00 0.01 0.02 0.03 0.00 0.02 0.02 - 0.00

Annual Balance Sheets for Tempest Therapeutics

This table presents Tempest Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 139 123 20 84 75 23 73 46 52 41 17
Total Current Assets		 130 116 20 83 71 20 69 33 40 31 8.27
Cash & Equivalents		 43 44 18 73 62 19 52 31 39 30 7.71
Prepaid Expenses		 3.00 2.06 1.08 3.37 6.34 1.01 2.13 1.27 1.13 1.21 0.56
Other Current Assets		 - - - - - - 15 0.45 0.00 0.00 0.00
Plant, Property, & Equipment, net		 8.31 5.57 0.00 0.00 0.00 1.11 1.11 1.06 0.84 0.89 0.61
Total Noncurrent Assets		 0.44 0.53 0.07 0.65 3.84 1.93 3.16 12 10 9.13 8.06
Other Noncurrent Operating Assets		 0.00 0.46 0.07 0.65 3.84 1.93 3.16 12 10 9.13 8.06
Total Liabilities & Shareholders' Equity		 139 123 20 84 75 23 73 46 52 41 17
Total Liabilities		 12 14 4.83 11 15 4.95 37 28 25 22 10
Total Current Liabilities		 11 13 4.09 9.82 13 3.22 20 7.28 9.41 14 3.31
Short-Term Debt		 - - 0.17 0.19 0.21 - - 0.00 4.29 6.35 0.00
Accounts Payable		 3.35 2.18 1.30 2.00 1.50 1.07 0.99 1.11 0.85 2.45 1.04
Accrued Expenses		 7.89 11 2.62 7.63 9.07 0.67 1.59 2.96 1.67 2.73 0.94
Dividends Payable		 - - - - - 0.00 0.09 0.10 0.11 0.06 0.00
Current Employee Benefit Liabilities		 - - - - - 0.70 0.91 1.25 1.54 1.76 0.15
Other Current Liabilities		 - - - - 1.75 0.79 16 1.86 0.95 0.87 1.19
Total Noncurrent Liabilities		 0.52 1.12 0.74 1.14 2.58 1.73 17 21 15 8.14 6.95
Other Noncurrent Operating Liabilities		 0.52 1.12 0.14 0.75 2.41 1.73 2.03 10 9.16 8.14 6.95
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 127 108 -129 73 60 -69 36 18 27 19 6.67
Total Preferred & Common Equity		 127 108 -131 71 59 -69 36 18 27 19 6.67
Total Common Equity		 127 108 -131 71 59 -69 36 18 27 19 6.67
Common Stock		 295 358 6.19 235 267 2.97 136 154 192 226 240
Retained Earnings		 -168 -250 -137 -164 -209 -72 -100 -136 -165 -207 -233

Quarterly Balance Sheets for Tempest Therapeutics

This table presents Tempest Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 24 44 42 34 32 24 17 11
Total Current Assets		 12 33 32 24 22 15 8.10 2.45
Cash & Equivalents		 11 32 31 22 22 14 7.51 1.81
Prepaid Expenses		 1.17 1.17 0.42 1.44 0.92 0.82 0.59 0.64
Other Current Assets		 0.00 - 0.00 0.00 - 0.00 - 0.00
Plant, Property, & Equipment, net		 0.92 0.92 1.01 0.93 0.82 0.75 0.68 0.55
Total Noncurrent Assets		 11 9.96 9.61 9.35 8.91 8.63 8.34 7.76
Other Noncurrent Operating Assets		 11 9.96 9.61 9.35 8.91 8.63 8.34 7.76
Total Liabilities & Shareholders' Equity		 24 44 42 34 32 24 17 11
Total Liabilities		 25 24 25 22 21 15 11 9.93
Total Current Liabilities		 7.42 11 15 14 13 7.14 3.53 3.31
Short-Term Debt		 2.13 6.46 8.65 8.50 4.19 0.00 0.00 0.00
Accounts Payable		 1.14 1.05 1.36 1.70 2.19 4.72 0.92 0.59
Accrued Expenses		 2.00 1.52 2.38 1.46 4.99 1.22 1.35 1.16
Dividends Payable		 0.11 0.11 0.11 0.08 0.04 0.00 0.00 0.00
Current Employee Benefit Liabilities		 0.93 0.69 1.13 1.40 0.72 0.10 0.10 0.33
Other Current Liabilities		 1.12 0.86 0.94 0.83 1.06 1.10 1.15 1.24
Total Noncurrent Liabilities		 18 13 11 8.41 7.85 7.56 7.26 6.62
Capital Lease Obligations		 9.38 - - - - 7.56 - 6.62
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1.19 21 17 11 11 9.78 6.35 0.82
Total Preferred & Common Equity		 -1.19 21 17 11 11 9.78 6.35 0.82
Total Common Equity		 -1.19 21 17 11 11 9.78 6.35 0.82
Common Stock		 157 194 200 205 229 236 236 271
Retained Earnings		 -158 -173 -183 -193 -218 -226 -229 -270

Annual Metrics And Ratios for Tempest Therapeutics

This table displays calculated financial ratios and metrics derived from Tempest Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 27,278,284.00 35,608,386.00 35,705,722.00 35,826,429.00 13,472,937.00 18,999,701.00 6,910,324.00 10,517,099.00 19,247,495.00 43,642,072.00 4,440,161.00
DEI Adjusted Shares Outstanding		 2,098,330.00 2,739,107.00 2,746,594.00 2,755,879.00 1,036,380.00 1,461,515.00 531,563.00 809,008.00 1,480,577.00 3,357,082.00 4,440,161.00
DEI Earnings Per Adjusted Shares Outstanding		 -34.89 -30.03 -30.79 -9.87 -43.00 -13.14 -53.24 -44.14 -19.92 -12.46 -5.91
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 135.74% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -44.79% -12.52% -7.60% 67.95% -64.95% 57.85% -41.89% -25.55% 17.31% -45.11% 35.75%
EBIT Growth		 -45.81% -12.71% -3.85% 67.92% -68.64% 58.08% -41.33% -26.17% 17.74% -44.52% 35.71%
NOPAT Growth		 -50.21% -12.52% -4.09% 68.13% -68.93% 57.49% -39.84% -28.36% 15.83% -44.14% 36.77%
Net Income Growth		 -47.86% -12.35% -2.83% 67.87% -63.99% 56.90% -47.34% -26.17% 17.41% -41.88% 37.24%
EPS Growth		 -23.29% 5.19% -12,470.70% 94.54% 81.51% -1,162.46% 81.79% 58.63% 38.19% -41.88% 67.54%
Operating Cash Flow Growth		 -64.40% -22.77% 67.05% -16.26% -74.32% 53.87% -36.49% -19.71% 11.96% -20.73% 18.79%
Free Cash Flow Firm Growth		 -68.03% 7.51% -24.50% 73.73% -95.33% 51.23% -21.29% -15.08% 4.01% -24.59% 15.84%
Invested Capital Growth		 91.22% -1,291.74% 70.06% -115.43% 18.82% 72.25% 39.18% -381.13% 32.10% -162.72% 78.03%
Revenue Q/Q Growth		 130.83% -5.23% -100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -2.15% -4.83% -35.14% 55.62% -4.99% 23.26% 0.02% -2.87% 4.91% -19.29% 27.05%
EBIT Q/Q Growth		 -2.81% -4.28% -30.88% 54.64% -7.31% 22.82% -0.05% -3.17% 5.27% -18.95% 26.81%
NOPAT Q/Q Growth		 -2.79% -2.70% -31.16% 54.90% -7.42% 22.09% 0.08% -4.83% 4.64% -17.98% 27.03%
Net Income Q/Q Growth		 -2.39% -2.55% -29.95% 54.29% -6.81% 45.67% -65.77% -3.85% 5.19% -17.81% 27.16%
EPS Q/Q Growth		 2.53% 5.54% -17,878.21% 94.89% -193.93% -69.90% 79.88% -133.26% 5.91% -17.81% 22.04%
Operating Cash Flow Q/Q Growth		 -1.61% -6.28% 61.29% -939.14% -6.36% 28.06% -16.68% 4.62% 1.10% -13.68% 19.69%
Free Cash Flow Firm Q/Q Growth		 -3.11% 4.26% -48.27% 61.78% -10.89% 16.67% -3.03% 8.49% 27.07% -74.55% 15.55%
Invested Capital Q/Q Growth		 -1,310.81% -213.00% 55.94% -69.85% -25.10% 0.00% 51.28% -4,318.33% -123.42% -128.23% 11.04%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -711.91% -727.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -25,127.44% -11,993.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -25,992.42% -12,406.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -25,999.64% -12,431.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -26,432.85% -12,597.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.10% 100.24% 100.00% 100.00% 100.00% 100.47% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.56% 101.09% 100.34% 100.50% 97.72% 100.00% 104.74% 104.75% 105.17% 103.25% 100.79%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -80.38% -69.99% -63.43% -23.47% -67.02% -49.39% -104.76% -131.70% -131.42% -182.35% -203.63%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -70.54% -62.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -71.72% -63.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -80.38% -69.99% 5.35% 6.05% -65.26% 6.51% 63.36% -131.70% -131.42% -182.35% -203.63%
Return on Equity Simple (ROE_SIMPLE)		 -57.72% -76.01% 64.72% -38.30% -76.12% 27.92% -78.36% -197.17% -110.17% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -50 -57 -59 -19 -32 -14 -19 -24 -20 -29 -19
NOPAT Margin		 -18,194.69% -8,684.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -24.31% -21.14% -18.60% -7.04% -18.23% -13.91% -33.92% -39.91% -36.82% -47.40% -48.54%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -54.69% -115.46% -278.98%
Cost of Revenue to Revenue		 811.91% 827.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 18,625.99% 7,537.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 6,654.51% 3,314.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 25,280.51% 11,679.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -72 -81 -84 -27 -46 -19 -27 -34 -28 -41 -26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -70 -78 -84 -27 -45 -19 -27 -33 -28 -40 -26
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.10 0.50 0.00 4.01 1.55 0.00 1.01 0.67 3.16 1.90 1.91
Price to Tangible Book Value (P/TBV)		 2.10 0.50 0.00 4.01 1.55 0.00 1.01 0.67 3.16 1.90 1.91
Price to Revenue (P/Rev)		 962.13 83.43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 504.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.01 0.01 0.00 0.42 0.57 0.39 0.33 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.01 0.00 0.00 0.42 0.57 0.23 0.00 0.00
Financial Leverage		 -1.03 -1.03 -1.03 -1.03 -1.05 -1.05 -1.03 -1.06 -1.10 -1.14 -1.22
Leverage Ratio		 1.12 1.11 0.53 0.45 1.20 1.26 1.78 2.20 2.18 2.03 2.26
Compound Leverage Factor		 1.14 1.12 0.54 0.45 1.17 1.26 1.86 2.30 2.29 2.09 2.28
Debt to Total Capital		 0.00% 0.00% 0.49% 0.78% 0.62% 0.00% 29.44% 36.41% 28.27% 24.94% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.11% 0.26% 0.35% 0.00% 0.00% 0.00% 11.48% 24.94% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.38% 0.52% 0.28% 0.00% 29.44% 36.41% 16.79% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 181.58% 2.95% 2.20% 484.02% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% -82.06% 96.28% 97.18% -384.02% 70.56% 63.59% 71.73% 75.06% 100.00%
Debt to EBITDA		 0.00 0.00 -0.01 -0.02 -0.01 0.00 -0.57 -0.31 -0.38 -0.16 0.00
Net Debt to EBITDA		 0.00 0.00 0.20 2.86 1.42 0.00 1.38 0.62 1.04 0.60 0.00
Long-Term Debt to EBITDA		 0.00 0.00 -0.01 -0.01 0.00 0.00 -0.57 -0.31 -0.23 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.01 -0.03 -0.01 0.00 -0.80 -0.43 -0.52 -0.22 0.00
Net Debt to NOPAT		 0.00 0.00 0.29 4.10 1.99 0.00 1.95 0.86 1.41 0.81 0.00
Long-Term Debt to NOPAT		 0.00 0.00 -0.01 -0.02 -0.01 0.00 -0.80 -0.43 -0.31 0.00 0.00
Altman Z-Score		 11.21 -1.75 -16.56 12.86 -1.36 -1.35 -1.74 -5.64 -3.51 -8.74 -23.28
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 108.43% 125.79% 2.63% 113.17% 160.48% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.55 8.82 4.82 8.50 5.68 6.15 3.44 4.53 4.29 2.21 2.50
Quick Ratio		 11.27 8.66 4.30 7.91 4.99 5.84 2.59 4.29 4.17 2.13 2.33
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -55 -51 -63 -17 -33 -16 -19 -22 -21 -26 -22
Operating Cash Flow to CapEx		 -961.68% -2,387.24% -508,500.00% -65,686.11% -10,383.38% -38,034.00% -19,227.41% -5,528.83% -16,092.35% -7,592.41% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -220.13 0.00 0.00 0.00 -15.01 -13.69 -14.67 -20.13 -107.69
Operating Cash Flow to Interest Expense		 0.00 0.00 -70.63 0.00 0.00 0.00 -20.25 -19.20 -18.88 -25.10 -129.57
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -70.64 0.00 0.00 0.00 -20.35 -19.55 -19.00 -25.43 -129.57
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.05 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.77 1.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 476.50 187.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -476.50 -187.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.45 -6.24 -1.87 -4.02 -3.27 -0.91 -0.55 -2.65 -1.80 -4.73 -1.04
Invested Capital Turnover		 -0.10 -0.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 4.66 -5.79 4.37 -2.16 0.76 2.36 0.36 -2.10 0.85 -2.93 3.69
Enterprise Value (EV)		 140 -60 322 210 29 109 -0.27 -8.76 56 13 5.04
Market Capitalization		 267 54 50 285 91 41 36 12 85 36 13
Book Value per Share		 $4.65 $3.04 ($3.66) $1.98 $4.35 ($3.62) $5.23 $1.72 $1.39 $0.44 $1.50
Tangible Book Value per Share		 $4.65 $3.04 ($3.66) $1.98 $4.35 ($3.62) $5.23 $1.72 $1.39 $0.44 $1.50
Total Capital		 127 108 159 74 60 18 51 28 37 25 6.67
Total Debt		 0.00 0.00 0.77 0.57 0.38 0.00 15 10 11 6.35 0.00
Total Long-Term Debt		 0.00 0.00 0.60 0.38 0.17 0.00 15 10 6.26 0.00 0.00
Net Debt		 -127 -114 -17 -77 -63 -19 -37 -21 -29 -24 -7.71
Capital Expenditures (CapEx)		 5.23 2.59 0.00 0.04 0.40 0.05 0.14 0.56 0.17 0.44 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.24 -11 -1.80 -3.92 -4.69 -2.22 -2.89 -5.56 -3.99 -6.66 -2.75
Debt-free Net Working Capital (DFNWC)		 119 103 16 74 59 17 49 26 35 24 4.96
Net Working Capital (NWC)		 119 103 16 74 59 17 49 26 31 17 4.96
Net Nonoperating Expense (NNE)		 23 26 26 8.37 13 5.70 9.41 11 9.08 12 7.66
Net Nonoperating Obligations (NNO)		 -127 -114 -160 -77 -63 -19 -37 -21 -29 -24 -7.71
Total Depreciation and Amortization (D&A)		 2.42 2.86 0.03 0.03 1.05 0.34 0.37 0.64 0.38 0.39 0.27
Debt-free, Cash-free Net Working Capital to Revenue		 -2,975.09% -1,707.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 42,822.38% 15,809.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 42,822.38% 15,809.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.70) ($2.56) ($1.43) ($17.58) ($3.25) ($1.93) ($7.47) ($3.09) ($1.91) ($19.50) ($6.33)
Adjusted Weighted Average Basic Shares Outstanding		 27.30M 35.64M 35.73M 13.36M 18.27M 19.04M 3.79M 11.55M 15.42M 2.15M 4.15M
Adjusted Diluted Earnings per Share		 ($2.70) ($2.56) ($1.43) ($17.58) ($3.25) ($1.93) ($7.47) ($3.09) ($1.91) ($19.50) ($6.33)
Adjusted Weighted Average Diluted Shares Outstanding		 27.30M 35.64M 35.73M 13.36M 18.27M 19.04M 3.79M 11.55M 15.42M 2.15M 4.15M
Adjusted Basic & Diluted Earnings per Share		 ($2.70) ($2.56) ($1.43) ($17.58) ($3.25) ($1.93) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 27.09M 32.15M 35.68M 1.55M 13.71M 18.86M 7.17M 10.56M 22.19M 3.50M 14.34M
Normalized Net Operating Profit after Tax (NOPAT)		 -50 -53 -59 -19 -32 -14 -19 -24 -20 -29 -19
Normalized NOPAT Margin		 -18,194.69% -8,105.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -26,405.78% -12,566.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -292.70 0.00 0.00 0.00 -21.08 -21.07 -19.35 -30.80 -125.87
NOPAT to Interest Expense		 0.00 0.00 -204.96 0.00 0.00 0.00 -14.73 -14.99 -14.09 -22.35 -89.87
EBIT Less CapEx to Interest Expense		 0.00 0.00 -292.72 0.00 0.00 0.00 -21.18 -21.42 -19.47 -31.13 -125.87
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -204.97 0.00 0.00 0.00 -14.84 -15.33 -14.20 -22.68 -89.87
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -2.97% -0.03% -2.44% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Tempest Therapeutics

This table displays calculated financial ratios and metrics derived from Tempest Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 13,324,065.00 19,247,495.00 22,192,026.00 22,217,265.00 25,207,792.00 43,642,072.00 45,483,384.00 3,682,428.00 4,440,161.00 4,440,161.00 14,344,034.00
DEI Adjusted Shares Outstanding		 1,024,928.00 1,480,577.00 1,707,079.00 1,709,020.00 1,939,061.00 3,357,082.00 3,498,722.00 3,682,428.00 4,440,161.00 4,440,161.00 14,344,034.00
DEI Earnings Per Adjusted Shares Outstanding		 -6.62 -5.06 -4.63 -5.60 -5.44 -4.11 -3.10 -2.14 -0.79 -0.91 -1.93
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 24.31% 16.89% -3.92% -26.60% -60.16% -92.39% -42.74% 14.22% 65.99% 70.73% -159.96%
EBIT Growth		 25.06% 17.99% -3.35% -27.29% -59.47% -90.77% -41.97% 14.94% 65.67% 70.36% -158.87%
NOPAT Growth		 24.84% 15.89% -5.18% -28.27% -60.06% -85.24% -37.15% 16.87% 65.91% 70.72% -153.47%
Net Income Growth		 24.15% 17.74% -3.51% -26.24% -55.56% -84.47% -37.40% 17.76% 66.74% 70.89% -155.03%
EPS Growth		 27.27% 26.09% -3.51% -26.24% -55.56% -84.47% -37.40% 62.50% 85.15% 84.94% 19.94%
Operating Cash Flow Growth		 28.49% 4.69% 13.45% 13.80% -56.96% -64.36% -11.83% -53.01% 33.42% 64.78% 5.45%
Free Cash Flow Firm Growth		 -71.43% -47.11% 112.96% 72.75% 119.20% -11.51% -164.12% -127.20% -244.18% 3.98% -1,152.90%
Invested Capital Growth		 12,911.67% 32.10% -111.63% -68.85% -126.95% -162.72% -523.94% 189.40% 43.63% 78.03% 191.55%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 11.45% -11.08% -6.01% -21.42% -12.02% -33.44% 21.35% 27.03% 55.59% -14.83% -598.58%
EBIT Q/Q Growth		 11.25% -10.88% -5.98% -22.05% -11.19% -32.65% 21.13% 26.87% 55.13% -14.53% -588.78%
NOPAT Q/Q Growth		 11.75% -13.99% -6.12% -20.17% -10.11% -31.92% 21.43% 27.16% 54.85% -13.32% -580.05%
Net Income Q/Q Growth		 10.49% -10.34% -5.56% -21.08% -10.30% -30.85% 21.38% 27.53% 55.39% -14.53% -588.78%
EPS Q/Q Growth		 11.11% 29.17% -5.56% -21.08% -10.30% -30.85% 21.38% 34.49% 61.84% -22.78% -160.82%
Operating Cash Flow Q/Q Growth		 -1.49% 4.81% -16.37% 23.32% -84.79% 0.32% 20.82% -4.92% 19.59% 47.28% -112.59%
Free Cash Flow Firm Q/Q Growth		 36.57% 50.57% 163.53% -236.79% 144.69% -387.12% 63.47% -384.70% 71.64% -91.22% -376.64%
Invested Capital Q/Q Growth		 478.86% -123.42% 45.22% -247.46% 39.52% -128.23% -30.09% 149.79% -138.13% 11.04% 642.06%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 105.82% 105.30% 104.88% 104.04% 103.22% 101.82% 101.50% 100.59% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -243.18% -131.42% -188.37% -289.26% -691.89% -182.35% -282.07% -322.57% -405.03% -203.63% -721.00%
Cash Return on Invested Capital (CROIC)		 -379.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,203.05% 0.00% 0.00% -748.13%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -243.18% -131.42% -188.37% -289.26% -691.89% -182.35% -282.07% -322.57% -405.03% -203.63% -721.00%
Return on Equity Simple (ROE_SIMPLE)		 2,613.95% 0.00% -144.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.61 -5.26 -5.58 -6.71 -7.39 -9.74 -7.66 -5.58 -2.52 -2.85 -19
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -24.19% -9.03% -19.27% -20.89% -136.30% -15.53% -16.48% -16.94% -9.44% -7.40% -132.95%
Return On Investment Capital (ROIC_SIMPLE)		 - -14.09% -17.87% -24.31% -37.00% -38.24% -49.96% -32.15% -39.68% -42.79% -260.90%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -6.41 -7.11 -7.54 -9.20 -10 -14 -11 -7.82 -3.51 -4.02 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.33 -7.03 -7.45 -9.04 -10 -14 -11 -7.76 -3.45 -3.96 -28
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 3.16 4.21 2.87 3.08 1.90 3.02 2.56 7.19 1.91 28.62
Price to Tangible Book Value (P/TBV)		 0.00 3.16 4.21 2.87 3.08 1.90 3.02 2.56 7.19 1.91 28.62
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.67 0.00 0.00 0.00 0.00 0.00 0.00 5.98 0.00 0.00 5.03
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -16.71 0.39 0.51 0.63 0.74 0.33 0.38 0.77 0.00 0.00 8.05
Long-Term Debt to Equity		 -14.92 0.23 0.20 0.12 0.00 0.00 0.00 0.77 0.00 0.00 8.05
Financial Leverage		 -0.70 -1.10 -0.76 -1.25 -0.45 -1.14 -1.22 -1.01 -1.18 -1.22 -1.04
Leverage Ratio		 3.41 2.18 2.59 3.32 5.63 2.03 2.41 2.49 2.86 2.26 3.59
Compound Leverage Factor		 3.61 2.29 2.71 3.46 5.81 2.07 2.45 2.51 2.86 2.26 3.59
Debt to Total Capital		 106.36% 28.27% 33.94% 38.61% 42.60% 24.94% 27.34% 43.59% 0.00% 0.00% 88.95%
Short-Term Debt to Total Capital		 11.41% 11.48% 20.68% 31.33% 42.60% 24.94% 27.34% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 94.95% 16.79% 13.26% 7.28% 0.00% 0.00% 0.00% 43.59% 0.00% 0.00% 88.95%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -6.36% 71.73% 66.06% 61.39% 57.40% 75.06% 72.66% 56.41% 100.00% 100.00% 11.05%
Debt to EBITDA		 -0.68 -0.38 -0.38 -0.36 -0.25 -0.16 -0.10 -0.18 0.00 0.00 -0.15
Net Debt to EBITDA		 -0.30 1.04 0.78 0.69 0.40 0.60 0.40 0.16 0.00 0.00 -0.11
Long-Term Debt to EBITDA		 -0.61 -0.23 -0.15 -0.07 0.00 0.00 0.00 -0.18 0.00 0.00 -0.15
Debt to NOPAT		 -0.93 -0.52 -0.51 -0.48 -0.34 -0.22 -0.13 -0.25 0.00 0.00 -0.22
Net Debt to NOPAT		 -0.41 1.41 1.05 0.92 0.55 0.81 0.55 0.22 0.00 0.00 -0.16
Long-Term Debt to NOPAT		 -0.83 -0.31 -0.20 -0.09 0.00 0.00 0.00 -0.25 0.00 0.00 -0.22
Altman Z-Score		 -9.75 -2.17 -3.21 -5.15 -7.71 -6.59 -9.28 -12.56 -16.56 -18.98 -42.36
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.66 4.29 3.13 2.17 1.69 2.21 1.70 2.12 2.30 2.50 0.74
Quick Ratio		 1.50 4.17 3.02 2.14 1.58 2.13 1.63 2.00 2.13 2.33 0.55
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12 -6.11 3.88 -5.31 2.37 -6.81 -2.49 -12 -3.42 -6.54 -31
Operating Cash Flow to CapEx		 0.00% -88,214.29% -4,277.38% -2,212.85% -67,880.00% -338,300.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -33.14 -16.21 10.55 -14.28 7.21 -27.59 -15.46 -262.29 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -17.39 -16.38 -19.53 -14.81 -30.95 -41.09 -49.91 -183.28 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -17.39 -16.40 -19.98 -15.48 -30.99 -41.10 -49.91 -183.28 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 7.69 -1.80 -0.99 -3.43 -2.07 -4.73 -6.15 3.06 -1.17 -1.04 5.63
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 7.75 0.85 -9.46 -1.40 -9.76 -2.93 -5.17 6.49 0.90 3.69 12
Enterprise Value (EV)		 13 56 65 28 22 13 16 18 38 5.04 28
Market Capitalization		 4.06 85 87 49 35 36 34 25 46 13 24
Book Value per Share		 ($0.09) $1.39 $0.93 $0.76 $0.45 $0.44 $0.24 $2.66 $1.43 $1.50 $0.06
Tangible Book Value per Share		 ($0.09) $1.39 $0.93 $0.76 $0.45 $0.44 $0.24 $2.66 $1.43 $1.50 $0.06
Total Capital		 19 37 31 28 20 25 15 17 6.35 6.67 7.44
Total Debt		 20 11 11 11 8.50 6.35 4.19 7.56 0.00 0.00 6.62
Total Long-Term Debt		 18 6.26 4.14 2.01 0.00 0.00 0.00 7.56 0.00 0.00 6.62
Net Debt		 8.77 -29 -22 -20 -14 -24 -17 -6.72 -7.51 -7.71 4.81
Capital Expenditures (CapEx)		 0.00 0.01 0.17 0.25 0.02 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.12 -3.99 -3.06 -5.49 -4.03 -6.66 -8.07 -6.32 -2.94 -2.75 -2.67
Debt-free Net Working Capital (DFNWC)		 7.00 35 29 26 18 24 13 7.96 4.58 4.96 -0.87
Net Working Capital (NWC)		 4.87 31 23 17 9.58 17 9.26 7.96 4.58 4.96 -0.87
Net Nonoperating Expense (NNE)		 2.17 2.23 2.32 2.86 3.17 4.07 3.20 2.29 0.99 1.17 8.29
Net Nonoperating Obligations (NNO)		 8.88 -29 -22 -20 -14 -24 -17 -6.72 -7.51 -7.71 4.81
Total Depreciation and Amortization (D&A)		 0.09 0.09 0.09 0.16 0.10 0.05 0.07 0.07 0.07 0.07 0.06
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.48) ($0.34) ($4.68) ($5.46) ($5.33) ($83.72) ($3.16) ($2.07) ($0.79) ($0.97) ($2.53)
Adjusted Weighted Average Basic Shares Outstanding		 14.12M 15.42M 1.71M 1.73M 1.99M 165.10K 3.44M 3.80M 4.44M 4.15M 10.93M
Adjusted Diluted Earnings per Share		 ($0.48) ($0.34) ($4.68) ($5.46) ($5.33) ($83.72) ($3.16) ($2.07) ($0.79) ($0.97) ($2.53)
Adjusted Weighted Average Diluted Shares Outstanding		 14.12M 15.42M 1.71M 1.73M 1.99M 165.10K 3.44M 3.80M 4.44M 4.15M 10.93M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($83.72) $0.00 $0.00 $0.00 ($0.97) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 19.25M 22.19M 1.71M 1.94M 3.36M 3.50M 3.68M 4.44M 4.44M 14.34M 14.81M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.61 -5.26 -5.58 -6.71 -7.39 -9.74 -7.66 -5.58 -2.52 -2.85 -19
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -17.19 -18.86 -20.48 -24.73 -31.09 -54.92 -66.45 -170.09 0.00 0.00 0.00
NOPAT to Interest Expense		 -12.37 -13.95 -15.17 -18.03 -22.45 -39.45 -47.55 -121.22 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -17.19 -18.88 -20.93 -25.40 -31.13 -54.94 -66.45 -170.09 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -12.37 -13.97 -15.62 -18.70 -22.49 -39.46 -47.55 -121.22 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Tempest Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Tempest Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Tempest Therapeutics' net income appears to be on a downward trend, with a most recent value of -$26.26 million in 2025, falling from -$73.22 million in 2015. The previous period was -$41.84 million in 2024. View Tempest Therapeutics' forecast to see where analysts expect Tempest Therapeutics to go next.

Tempest Therapeutics' total operating income in 2025 was -$26.58 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $26.58 million

Over the last 10 years, Tempest Therapeutics' total revenue changed from $277 thousand in 2015 to $0.00 in 2025, a change of -100.0%.

Tempest Therapeutics' total liabilities were at $10.26 million at the end of 2025, a 54.1% decrease from 2024, and a 12.8% decrease since 2015.

In the past 10 years, Tempest Therapeutics' cash and equivalents has ranged from $7.71 million in 2025 to $73.29 million in 2018, and is currently $7.71 million as of their latest financial filing in 2025.

Over the last 10 years, Tempest Therapeutics' book value per share changed from 4.65 in 2015 to 1.50 in 2025, a change of -67.7%.


Related Companies

Financial statements for NASDAQ:TPST last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel